Skip to main content
Log in

Biological insights from clinical trials with anti-TNF therapy

  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alvaro-Garcia JM, Zvaifler NJ, Brown CB, Kaushansky L, Firestein GS (1991) Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNFα. J Immunol 146: 3365

    Google Scholar 

  2. Black RA, Rauch CT, Kozlosky C, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour necrosis factor α from cells. Nature 385: 729

    Google Scholar 

  3. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF α antibodies on synovial cell interleukin-I production in rheumatoid arthritis. Lancet II: 244

    Google Scholar 

  4. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 73:449

    Google Scholar 

  5. Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNFα antibody with the IL-1 receptor antagonist. Eur Cytokine Netw 6: 225

    Google Scholar 

  6. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, Woody JN, Feldmann M, Maini RN (1988) Regulation of cytokines and acute phase proteins following TNFα blockade in rheumatoid arthritis (in press)

  7. Chiller JM, Habicht GS, Weigle WO (1970) Cellular sites of immunologic unresponsiveness. Proc Natl Acad Sci USA 65: 551

    Google Scholar 

  8. Christen U, Thuerkauf R, Lesslauer W (1998) Immunogenicity of a human TNFR55-IgG1 fusion protein (Lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients [Abstract]. J Interferon Cytokine Res 18: A

  9. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34: 1125

    Google Scholar 

  10. Constantin A, Loubet-Lescoulie P, Lambert N, Coppin N, Mazieres B, Cantagrel A (1997) Cytokines expression assessed by competitive RT-PCR in rheumatoid arthritis: in vitro modulation by methotrexate. Arthritis Rheum 39: 5126

    Google Scholar 

  11. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases. Arthritis Rheum 35:1160

    Google Scholar 

  12. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, Fujita K, Lipsky PE (1995) Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 38: 96

    Google Scholar 

  13. Cutolo M, Kirkham B, Bologna C, Sany J, Scott D, Books P, Forre O, Jain R, Kvien T, Markenson J, Seibold J, Sturrock R, Veys E, Edwards J, Zang M, Durrwell L, Bisschops C, St Clair P, Milnarik B, Baudin M, Van der Auwera P (1996) Loading/maintenance doses approach to neutralization of TNF by Lenercept (TNFR55-IgG1, Ro45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a double-blind placebo controlled phase II trial. Arthritis Rheum 39: S243

    Google Scholar 

  14. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ (1997) Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor a blockade. Br J Rheumatol 36: 950

    Google Scholar 

  15. Davis D, Charles PJ, Feldmann M, Maim RN, Elliott MJ (1998) Relationship between peripheral platelet count and circulating cytokine levels in rheumatoid arthritis (in press)

  16. Di Giovine FS, Nuki G, Duff GW (1988) Tumour necrosis factor in synovial exudates. Ann Rheum Dis 47:768

    Google Scholar 

  17. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody J (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 36:1681

    Google Scholar 

  18. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JE, Bijl H, Woody JN (1994) Randomised double blind comparison of a chimaeric monoclonal antibody to tumour necrosis factor α(cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105

    Google Scholar 

  19. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125

    Google Scholar 

  20. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397

    Google Scholar 

  21. Feldmann M, Elliott MJ, Woody JN, Maini RN (1997) Anti-tumour necrosis factor a therapy of rheumatoid arthritis. Adv Immunol 64:283

    Google Scholar 

  22. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A (1989) Antibodies to cachectin/tumour necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627

    Google Scholar 

  23. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B, Ziegler SF, Cosman D (1992) The IL-6 signal transducer, gp130: an oncostatin receptor and affinity converter for the LII receptor. Science 255: 1434

    Google Scholar 

  24. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Woolley K (1994) Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370: 555

    Google Scholar 

  25. Georgopoulos S, Plows D, Kollias G (1996) Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46: 86

    Google Scholar 

  26. Grell M, Douni E, Wajant H et al (1995) The transmembrane form of tumour necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793

    Google Scholar 

  27. Haworth B, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21: 2575

    Google Scholar 

  28. Hirano T (1998) Interleukin-6 and its receptor: ten years later. Int Rev Immunol 16: 249

    Google Scholar 

  29. Isler P, Vey E, Zhang JH, Dayer JM (1993) Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 4: 15

    Google Scholar 

  30. Katsikis P, Chu CQ, Brennan FM, Maini RN, Feldmann M (1994) Immunoregulatory role of interleukin 10 (IL-10) in rheumatoid arthritis. J Exp Med 179: 1517

    Google Scholar 

  31. Kishimoto T, Akira S, Tage T (1992) Interleukin-6 and its receptor: a paradigm for cytokines. Science 258:22

    Google Scholar 

  32. Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA (1997) Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6:491

    Google Scholar 

  33. Kremer JM (1994) The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 21:1

    Google Scholar 

  34. Ledermann JA, Begent RH, Massof C, Kelly AM, Adam T, Bagshawe KD (1991) A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer 47: 659

    Google Scholar 

  35. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdmer N, Nusslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis — Short term cellular and molecular effects. J Immunol 156:1646

    Google Scholar 

  36. Maini RN, Elliott MJ, Charles PJ, Feldmann M (1994) Immunological intervention reveals reciprocal soles for TNFα and IL-10 in rheumatoid arthritis and SLE. Springer Semin Immunopathol 16: 327

    Google Scholar 

  37. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1997) Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum 40: S126

    Google Scholar 

  38. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Randomized placebo-controlled trial of multiple intravenous infusions of anti-TNFα monoclonal antibody with or without weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (in press)

  39. Meade TW (1995) Fibrinogen in ischaemic heart disease. Eur Heart J 16 [Suppl A]: 31

    Google Scholar 

  40. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin adminstration. N Engl J Med 318:1481

    Google Scholar 

  41. Mohler K, Sleath PR, Fitzner IN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawama K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370: 218

    Google Scholar 

  42. Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, Everson MP, Daddona P, Ghrayeb J, Kilgrarriff C, Sanders ME, Koopman WJ (1993) Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 36: 307

    Google Scholar 

  43. Moreland LW, Margolies G, Heck LW Jr, Saway A, Blosch C, Hanna R, Koopman WJ (1996) Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 23: 1849

    Google Scholar 

  44. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141

    Google Scholar 

  45. Ohshima S, Saeki Y, Mima T, Suemura M, Ishida H, Shimizu M, McClosky R, Kishimoto T (1996) Possible mechanism for the long-term efficacy of anti-TNFα antibody (cA2) therapy in RA. Arthritis Rheum 39:S242

    Google Scholar 

  46. Oliver SJ, Banquerigo ML, Brahn E (1994) Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 157: 291

    Google Scholar 

  47. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum 39:1082

    Google Scholar 

  48. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldman M, Maini RN (1998) Reduction of angiogenic vascular endothelial growth factor following treatment of rheumatoid arthritis with anti-TNFα antibody. Arthritis Rheum 41:1258

    Google Scholar 

  49. Piguet PF, Gran GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510

    Google Scholar 

  50. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith SM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis. Br J Rheumatol 34: 334

    Google Scholar 

  51. Sander O, Rau R (1997) Long term observation of 80 patients treated with TNFα receptor-fusion protein (TNFR55-IgGI, RO45-2081). Arthritis Rheum 40: abstr. no. 1157: S224

    Google Scholar 

  52. Sander O, Rau R, Riel P van, Putte L van de, Hasler F, Baudin M, Ludin E, McAuliffe T, Dickinson S, Kahny M-R, Lesslauer W, Van der Auwera P (1996) Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45–2081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial. Arthritis Rheum 39: S242

    Google Scholar 

  53. Sander O, Broeder A den, Hoogen F van der, Laan R, Putte L van de, Rau R (1997) Thirty months of treatment with a TNFα receptor-fusion protein (TNFR55-IgG1, RO45-2081) in patients with severe refractory RA. Arthritis Rheum 40: abstr. no.301: S81

    Google Scholar 

  54. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA (1988) Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041

    Google Scholar 

  55. Slack JL, Reddy P, Peschon JJ, Stocking KL, Blanton RA, Black RA (1998) Tumour necrosis factor-α converting enzyme is involved in additional shedding events [Abstract]. J Interferon Cytokine Res 18: A

  56. Sommer N, Loschmann P-A, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dichgans J, Martin R (1995) The antidepressant rolipram suppresses Cyokine production and prevents autoimmune encephalomyelitis. Nat Med 1: 244

    Google Scholar 

  57. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301

    Google Scholar 

  58. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39: 1077

    Google Scholar 

  59. Taylor PC, Chapman P, Elliott MJ, Schaible TF, Peters AM, Feldmann M, Maini RN (1997) Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy. Arthritis Rheum 40: S80

    Google Scholar 

  60. Taylor P, Paleolog E, Chapman P, Elliott M, McCloskey RV, Peters M, Feldmann M, Maini RN (1998) TNFα blockade in patients with rheumatoid arthritis reduces granulocyte traffic to joints with concomitant reduction in synovial chemotactic gradients (in press)

  61. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375

    Google Scholar 

  62. Van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC (1995) A randomised, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38:1097

    Google Scholar 

  63. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784

    Google Scholar 

  64. Williams RO, Mason LJ, Feldmann M, Maini RN (1994) Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91: 2762

    Google Scholar 

  65. Williams RO, Ghrayeb J, Feldmann M, Maini RN (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84:433

    Google Scholar 

  66. Williams L, Gibbons DL, Gearing A, Feldmann M, Brennan FM (1996) Parodoxical effects of a synthetic metalloproteinase inhibitor which blocks both p55 and p75 TNF receptor shedding and TNFα processing. J Clin Invest 97: 2833

    Google Scholar 

  67. Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumour necrosis factor receptor Fe fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldmann, M., Charles, P., Taylor, P. et al. Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 20, 211–228 (1998). https://doi.org/10.1007/BF00832008

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00832008

Keywords

Navigation